To ask the Secretary of State for Health, pursuant to the Answers of 2 February 2015 to Questions 222495, 222494 and 222493, how many medicines were paid for by the industry rebate payments through the Pharmaceutical Price Regulation Scheme in 2014 in each (a) financial quarter and (b) therapeutic area.
The Mandate for 2015-16 has set a firm NHS England budget for 2015-16, which is £3 billion (3%) higher than its budget for 2014-15. This increase takes into account a number of things, including additional funding for the National Health Service announced in the Autumn Statement and the fact that the Pharmaceutical Price Regulation Scheme (PPRS) payment in 2015-16 is now forecast to be higher than originally expected.
All the PPRS payments go back into spending on improving patients’ health and care and it will be up to NHS England how they split that overall budget between clinical commissioning groups, specialised commissioning etc. Following normal Government accounting rules, there is no separately identified ring-fenced funding stream associated with the PPRS payment. Accordingly, it would not be possible to identify what or how many medicines are paid for by PPRS payments.
The Government believes that NHS commissioners and providers are best placed to decide how to allocate their budgets to deliver improvements in the outcomes for patients. The PPRS includes a number of commitments for improving patient outcomes and for improving patient access to clinically and cost effective medicines.